Midomafetamine
- Generic Name
- Midomafetamine
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
Role of Serotonin in Acute and Subacute MDMA Effects
- Conditions
- MDMA Mechanism of Action
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2013-05-31
- Target Recruit Count
- 13
- Registration Number
- NCT00838305
- Locations
- 🇺🇸
CPMC Research Institute, St.Luke's Hospital, San Francisco, California, United States
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Drug: 3,4-methyelendioxymethamphetamine (25 mg)Behavioral: Therapy
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Lykos Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT00353938
- Locations
- 🇨🇭
Offices of Peter Oehen MD, Biberist, Solothurn, Switzerland
MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer
- Conditions
- CancerAnxiety Disorder
- Interventions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT00252174
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- First Posted Date
- 2004-08-25
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Lykos Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT00090064
- Locations
- 🇺🇸
Offices of Michael Mithoefer MD, Mount Pleasant, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.